We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 16

Healthcare & life sciences private equity deal tracker: Argon Medical Devices completes acquisition of Angiotech Pharmaceuticals subsidiary

  • McGuireWoods LLP
  • -
  • Canada, USA
  • -
  • May 8 2013

Argon Medical Devices has completed its acquisition of the interventional products business of Angiotech Pharmaceuticals Inc., according to a news

Dental investing filling need for PE investing - Part I

  • McGuireWoods LLP
  • -
  • Canada, USA
  • -
  • April 24 2012

Dental practice management companies have been an increasing focus of private equity firms throughout the United States and Canada

Teva Canada Limited v. Wyeth LLC, December 9, 2011, 2011 FC 1442, venlafaxine

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • January 23 2012

This was a successful motion by the defendants to dismiss the plaintiff’s action for s.8 damages following a recent decision by Hughes J. (2011 FC 1169) in which he held that the plaintiff Teva was not permitted to continue ratiopharm’s claim for s. 8 damages following their merger

Teva Canada Limited v. Wyeth LLC et al, October 17, 2011, 2011 FC 1169, venlafaxine (motion for summary judgment)

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 18 2011

In response to a motion brought by Teva for summary judgment of the issue of whether Teva can continue a s. 8 claim initially brought by ratiopharm, Justice Hughes found that this case met the criteria for being brought in a summary nature and proceeded to find that in the circumstances Teva could not pursue the s.8 action and dismissed the action

Contract research organizations (CROs) go private; another segment of opportunity for investors?

  • McGuireWoods LLP
  • -
  • Canada
  • -
  • October 19 2011

PPDPharmaceutical Product Development, an international contract research firm that has just been named to the 2011 InformationWeek 500, is being taken private by affiliates of the Carlyle Group and Hellman & Friedman in a cash deal valued at $3.9 billion

Canadian biopharmaceutical and life science deals and investments 2010 review

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

The availability of seed and early-stage funding is critical to sciencebased research and development

Quebec establishes new venture capital fund to invest in biotech research

  • Shook Hardy & Bacon LLP
  • -
  • Canada
  • -
  • February 24 2011

Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research

Canada's venture capital market: an update

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 24 2010

The global venture capital (VC) market has been in turmoil since 2008's financial crisis

Biotech’s new backbone

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • July 26 2010

The funding difficulties for the biotechnology are well known, but financiers have come up with new and innovative ways to respond to these funding challenges - namely the Standby Equity Distribution Agreement ("SEDA"

More biopharma M&A in 2010, but healthy or distressed?

  • Torys LLP
  • -
  • Canada
  • -
  • December 31 2009

As blockbuster drugs began to come off patent, big pharmas fearing loss of revenue share rushed to couple with their counterparts in 2009

Current Search

Suggested Facets

Author

Firm Name

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy